Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glaukos Corp
(NY:
GKOS
)
129.28
+0.93 (+0.72%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Glaukos Corp
< Previous
1
2
3
Next >
Glaukos Announces FDA 510(k) Clearance of iPRIME™
January 06, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 29, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
December 20, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
November 19, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting
November 11, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation Announces Third Quarter 2021 Financial Results
November 04, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
October 14, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting
October 07, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
September 20, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
September 15, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™
September 03, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
August 26, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies
August 23, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation Announces Second Quarter 2021 Financial Results
August 05, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
July 22, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5
July 15, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule
July 14, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
June 10, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt
June 08, 2021
From
Glaukos
Via
Business Wire
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
May 19, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
May 18, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation Announces First Quarter 2021 Financial Results
May 05, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2020 Sustainability Report
April 27, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
April 22, 2021
From
Glaukos Corporation
Via
Business Wire
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
April 14, 2021
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.